Unfortunately, the terminology surrounding outcomes from treatment are a bit confusing. There are currently two outcomes from therapy which do not require treatment under current guidelines:
Partial cure: HBV DNA < 2000 IU/mL with normal liver function in the absence of antiviral therapy. This is akin to “inactive HBV infection”
Functional cure: HBV DNA and HBsAg are not detectable with normal liver function in the absence of antiviral therapy. For this outcome to persist, removal of most of the liver cells with integrated HBV DNA has to occur.
Both of these outcomes occur because immune control of HBV infection has recovered. This recovery is obviously much stronger in the case of functional cure.
So in the recently presented extended follow-up from NAP treatment of chronic HBV infection, overall immune control was maintained at 78% (this was present at 1 year of follow-up) but the proportion of patients who had functional cure of HBV increased from 39% at one year to 56% at 5.3 years.
HCC risk is the lowest in patients who achieve functional cure after antiviral therapy. Can HCC risk be eliminated, we are not sure but HBV DNA integration is the primary driver for HCC; the removal of these hepatocytes leading to functional cure must be having a positive impact.
I’ve moved your question into this thread about cure (please feel free to read the other responses to get a broader idea about what’s going on in this area). To answer your questions: